In the SEQUOIA-HCM RCT, adult patients with symptomatic obstructive hypertrophic cardiomyopathy receiving aficamten demonstrated significant improvement in LVOT gradients and measures of LV diastolic function in comparison to those receiving placebo, and these changes were

#ESCCONGRESS was a phenomenal meeting with lots of great science in #amyloid #HCM and #cardiomyopathies And visiting Oxford and JR was the icing on the cake. Thanks Betty Raman Christopher Toepfer et al for a memorable time

A milestone in #transthyretin #amyloidosis ACT-EARLY kicks off - acoramidis vs placebo for the prevention of #ATTR phenotype in patients at risk. clinicaltrials.gov/study/NCT06563… investor.bridgebio.com/static-files/6… #CardioTwitter

It is an exciting time to attend ASNC Society #ASNC2024 to learn the art of perfusion imaging in a multimodality settings, new research and meet new friends #CvNUV Rupa Sanghani Rami Doukky Cesia Gallegos, MD MHS Randall Thompson Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT Claudio Tinoco Mesquita Erin Stevens CNMT, NCT Bruno Lima

Thanks Ahmad for giving a terrific talk RDM Oxford! It was amazing to hear about your exciting research in HCM and look forward to inviting you over again to hear about the incredible progress you will have made in this space.

From #ESCCongress: In our third interview segment with Ahmad Masri, he highlighted a trio of aficamten-related studies providing insight into the effects of the cardiac myosin inhibitor in patients with oHCM. hcplive.com/view/aficamten… #Cardiomyopathy Cytokinetics

Impressive WMD for B cells

🎉#ASNC2024 is already in the Top 10 trending conferences on Symplur, and the meeting hasn't even started yet!📈 Excited by the buzz🐝 and can't wait for it to kick off tomorrow! #CVNuc #CardioTwitter #Austin #Texas

Published today in JAMA Cardiology. Cardiopulmonary Exercise Testing (#CPET) in clinical trials captures ∆es in ex. performance. In #oHCM, aficamten ↑peak VO2, ↑workload, ↑cardiac power, ↑ VO2 at AT & improved ventilatory efficiency. Our novel z-score integrating ∆pVO2 and

ASNC Society Symplur Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT Suman Tandon Mrin Shetty🫀📸 Claudio Tinoco Mesquita Dra. Isabel Carvajal. Ahmed Sami Abuzaid MD,EMHL,FACP,FASE,FESC,FACC Bruno Lima Ahmad Masri Lawrence Phillips Panithaya Chareonthaitawee MD #ASNC2024 #CVNuc we are at kickoff! Excited to hear more on the HELIOS-B results - siRNA therapies (Vutrisiran)

A real treat to have Ronald Witteles here with us at #ASNC2024 to present the results of HELIOS-B #CVNuc Alnylam Pharmaceuticals

What’s next for clinical trials in #HCM? Join Rosalyn Adigun, M.D., Pharm.D., M.Sc. & #JamesUdelson on October 27 at #HCMSummit8 to discover the future of research & how it will shape patient care. Secure your spot today: hcmsummit.org #hypertrophiccardiomyopathy #cardiotwitter #cardioed #cardiox

In 1 week! Don’t miss our next webinar featuring unique cases presented by the authors, with panel discussions following each case presentation, Sept. 12 at 4:00PM ET. Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT Ahmad Masri Barone-Rochette Gilles Jiwon Kim, MD Kaz Negishi@Cardiologist/ Heart Mafia Lucy Babak Nazer heart.zoom.us/webinar/regist…

Look at mortality in these groups. I wondered how did this trial continue? Investigators employed response-adaptive randomization strategy - see 2nd screenshot #CardioTwitter

Shifting from a career in academia to industry #ASNC2024 ASNC Society

On the heels of a stellar and eventful #ESC where #amyloid featured prominently, our #ATTR #FinalFour Young Investigators have been decided! Official announcement coming TOMORROW! Ahmad Masri Amyloidosis Speakers Bureau Amyloidosis Research Consortium

Excellent talk on “Genetics and Disparities in ATTR-CM” by Saurabh Malhotra Moderator expert panel Sarah Cuddy Brett Sperry, MD ASNC Society #ASNC2024